Lung Cancer Flashcards
How common is lung cancer?
Lung cancer is the third most common cancer in the UK behind breast and prostate
What are the 2 different histological types of lung cancer?
Clinically the most important division is between small cell (sclc) (20%) and non-small cell (nsclc) (80%).
What are the 3 different types of non-small cell lung cancer?
Non-small cell lung cancer:
- Adenocarcinoma (around 40%)
- Squamous cell carcinoma (around 30%)
- Large-cell carcinoma (around 10%)
What are small cell lung cancers?
Arise from endocrine cells (Kulchitsky cells), often secreting polypeptide hormones resulting in paraneoplastic syndromes (eg production of acth, Cushing’s syndrome).
What are the risk factors for lung cancer?
Includes cigarette smoking; exposure to tobacco smoke, radon gas, or asbestos; and the presence of COPD.
What are the signs of lung cancer?
- Cachexia
- Anaemia
- Clubbing
- Hpoa (hypertrophic pulmonary osteoarthropathy, causing wrist pain);
- Supraclavicular or axillary nodes
- Chest signs: none, or consolidation; collapse; pleural effusion
- Metastases: bone tenderness; hepatomegaly; confusion; fits; focal cns signs; cerebellar syndrome; proximal myopathy and peripheral neuropathy
What are the symptoms of lung cancer?
- Cough (80%)
- Haemoptysis (70%)
- Dyspnoea (60%)
- Chest pain (40%)
- Recurrent or slowly resolving pneumonia
- Lethargy
- Anorexia
- Weight loss
What investigations should be ordered for lung cancer?
- CXR
- Contrast enhanced CT scan
- PET-CT
- Bronchoscopy with endobronchial ultrasound (EBUS)
- Biopsy
Why investigate using CXR?
A standard posteroanterior (PA) chest x-ray is the first line investigation in suspected lung cancer.
Findings suggesting cancer include:
- Hilar enlargement
- “Peripheral opacity”- a visible lesion in the lung field
- Pleural effusion- usually unilateral in cancer
- Collapse
Why investigate using contrast enhanced CT?
A contrast-enhanced CT of the lower neck, chest, and upper abdomen is standard and helps to define the primary tumour and evaluate for regional spread.
Shows size, location and extent of primary tumour; evaluates for hilar and/or mediastinal lymphadenopathy and distant metastases.
Why investigate using PET-CT?
PET-CT (positron emission tomography) scans involve injecting a radioactive tracer (usually attached to glucose molecules) and taking images using a combination of a CT scanner and a gamma ray detector to visualise how metabolically active various tissues are. They are useful in identifying areas that the cancer has spread to by showing areas of increased metabolic activity suggestive of cancer.
Why investigate using bronchoscopy?
Bronchoscopy, typically performed with a flexible bronchoscope, is an endoscopic procedure in which the proximal bronchial tree can be directly visualised and suspicious areas biopsied.
Why investigate using bronchoscopy?
Pathological confirmation of malignancy is the only widely accepted method to make a definitive diagnosis of lung cancer. Tissue is sampled from bronchoscopy where possible
Briefly describe the staging of lung cancer
The TNM staging classification is first used, and then converted to the I-IV staging system which is used to guide management decisions.
Briefly describe the treatment of NSCLC
Note: stage I-III
Surgical management
- Options include lobectomy/pneumonectomy in patients with intact lung function, or wedge resection in patients with reduced lung function (e.g. elderly, underlying respiratory conditions)
Medical management
- Pre-operative chemotherapy
- Post-operative chemotherapy and radiotherapy: may not be needed in some cases of stage I lung cancer
If unsuitable for surgery (e.g. too frail), patients may be offered stereotactic ablative radiotherapy (SABR). Compared to conventional radiotherapy, SABR involves directing a more intense and focused beam of radiation at the tumour. This reduces the number of radiotherapy sessions needed and minimises damage to surrounding tissue.
Briefly describe the treatment of NSCLC
Note: stage IV
Targeted therapy
- These drugs target mutations which drive the pathogenesis of lung cancer .
Immunotherapy
- These drugs target immune checkpoints, which prevent the patient’s immune cells from killing tumour cells. For example, the immune checkpoint PD-L1 is targeted by pembrolizumab. Immunotherapy is an emerging field in cancer management.
Chemotherapy
- Especially important for patients who do not have any mutations which can be targeted by targeted therapies.
Palliative care
- Includes palliative radiotherapy, for metastases and symptom control.
Briefly describe the treatment of SCLC
Chemotherapy and radiotherapy.
Surgery: rare in small cell lung cancer, as most patients present with advanced disease.
Prophylactic cranial irradiation: since small cell lung cancer is associated with a high risk of brain metastases, radiotherapy is directed at the brain to prevent brain metastases.